医学部 耳鼻咽喉科学講座

翁長 龍太郎

オナガ リュウタロウ  (Ryutaro Onaga)

基本情報

所属
学校法人 自治医科大学 耳鼻咽喉科
(兼任) 臨床腫瘍科 助教
国立研究開発法人国立がん研究センター 東病院 頭頸部内科 外来研究員

研究者番号
50812864
ORCID ID
 https://orcid.org/0000-0002-6422-4033
J-GLOBAL ID
202401017612716574
researchmap会員ID
R000066410

学歴

 1

論文

 16
  • Ryutaro Onaga, Tomohiro Enokida, Hirofumi Kuno, Takashi Hiyama, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Yuta Hoshi, Takuma Kishida, Ryo Kuboki, Naohiro Takeshita, Hideki Tanaka, Hiroshi Nishino, Makoto Ito, Makoto Tahara
    Oral Oncology 165 107351-107351 2025年6月  筆頭著者
  • Ryutaro Onaga, Tomohiro Enokida, Shingo Sakashita, Nobukazu Tanaka, Yuta Hoshi, Takuma Kishida, Ryo Kuboki, Takao Fujisawa, Susumu Okano, Hiroshi Nishino, Makoto Ito, Genichiro Ishii, Shumpei Ishikawa, Makoto Tahara
    International Journal of Clinical Oncology 2025年4月10日  筆頭著者
  • Nobukazu Tanaka, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Hideki Tanaka, Ryutaro Onaga, Yuta Hoshi, Takuma Kishida, Akihisa Wada, Masanobu Sato, Naohiro Takeshita, Takeshi Fujisawa, Atsushi Motegi, Sadamoto Zenda, Tetsuo Akimoto, Makoto Tahara
    Oral Oncology 163 107235-107235 2025年4月  
  • Ryutaro Onaga, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Yuta Hoshi, Takuma Kishida, Hideki Tanaka, Masanobu Sato, Naohiro Takeshita, Ryo Kuboki, Hiroshi Nishino, Makoto Ito, Makoto Tahara
    International Journal of Clinical Oncology 2024年7月23日  筆頭著者
  • Yuta Hoshi, Tomohiro Enokida, Shingo Tamura, Torahiko Nakashima, Susumu Okano, Takao Fujisawa, Masanobu Sato, Akihisa Wada, Hideki Tanaka, Naohiro Takeshita, Nobukazu Tanaka, Ryutaro Onaga, Takuma Kishida, Hideoki Uryu, Shingo Sakashita, Takahiro Asakage, Makoto Tahara
    Frontiers in Oncology 14 2024年5月23日  
    Background Olfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the recurrent or metastatic (R/M) ONB population remains unclear. Methods We retrospectively evaluated 11 patients with R/M ONB who received any systemic chemotherapy at two Japanese institutions (National Cancer Center Hospital East and Kyushu Medical Center) between January 2002 and March 2022 and analyzed outcomes by use of anti-PD-1 antibody (nivolumab or pembrolizumab) monotherapy. Results Of the 11 patients, 6 received ICI (ICI-containing treatment group) and the remaining 5 were treated with systemic therapy but not including ICI (ICI-non-containing treatment group). Overall survival (OS) was significantly longer in the ICI-containing group (median OS: not reached vs. 6.4 months, log-rank p-value: 0.035). The fraction of ICI systemic therapy in the entire treatment period of this group reached 85.9%. Four patients (66.7%) in the ICI-containing treatment group experienced immune-related adverse events (irAE), with grades of 1/2. No irAE of grade 3 or more was seen, and no patient required interruption or discontinuation of treatment due to toxicity. Conclusion ICI monotherapy appears to be effective and to contribute to prolonged survival in R/M ONB.

MISC

 43
  • Nobukazu Tanaka Tomohiro, Enokida Susumu, Okano Takao, Fujisawa Ryutaro, Onaga Yuta, Hoshi Hideki Tanaka, Akihisa Wada, Masanobu Sato Naohiro, Takeshita Takeshi Fujisawa, Sadamoto Zenda, Makoto Tahara
    ESMO Asia Congress 2024_#2183 35 S1561-S1561 2024年12月  
  • Hirofumi Kuno, Takashi Hiyama, Tomoaki Sasaki, Shingo Sakashita, Ryutaro Onaga, Toshifumi Tomioka, Yoshihisa Muramatsu, Naruomi Akino, Hiroki Taguchi, Kotaro Sekiya, Tatsushi Kobayashi.
    RSNA2024 2024年12月  
  • 翁長 龍太郎, 榎田, 智弘, 檜山, 貴志, 田中, 伸和, 星, 裕太, 田中, 英基, 岸田, 拓磨, 藤澤, 孝夫, 岡野, 晋, 久野, 博文, 田原 信
    第48回頭頸部癌学会_第20群(画像) O-142 2024年6月  
  • Ryutaro Onaga, Tomohiro Enokida, Takashi Hiyama, Nobukazu Tanaka, Yuta Hoshi, Hideki Tanaka, Takao Fujisawa, Susumu Okano, Hirofumi Kuno, Makoto Tahara
    Journal of Clinical Oncology 42(16_suppl) 6034-6034 2024年6月1日  筆頭著者
    6034 Background: Extranodal extension (ENE) of nodal metastasis is a significant prognostic factor in p16-negative SCCHN and is classified as N3b by the AJCC 8th edition. Therefore, pretreatment determination of ENE has significant clinical implications in SCCHN, and iENE has just recently been proposed. We previously discussed association with pathological ENE and iENE (Jpn J Radiol. 2020;38(6):489-506.). However, the role of iENE in non-surgical sequential therapy remains unclear. Methods: We retrospectively reviewed patients with LASCCHN originating from the oropharynx, hypopharynx, and larynx who received enhanced computed tomography (CT), then treated with induction chemotherapy (IC) with paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy (CRT) from 2013 to 2022 in our hospital. Two radiologists specializing in head and neck cancer blindly annotated the status of iENE in baseline CT images by the previously reported criteria (Oral Oncol. 2022;125:105716.). Multivariate analysis variables for event-free survival (EFS) and overall survival (OS) included the presence or absence of iENE, a response to IC, clinical T-category, performance status, smoking status, etc. Results: In the 88 patients, 67 (76.1%) had iENE and 21 (23.9%) did not at baseline. In the former and latter group, stage II/III/IV were 10.4%/26.9%/62.7% and 0%/28.6%/71.4%, HPV-positive were 37.3% and 28.6%, respectively. With the median follow-up of 37.4 months (range: 6.7-108.8), the former had significantly shorter EFS (3-y EFS: 41.9% vs. 75.6%, hazard ratio [HR]; 2.9 (1.2-7.4), p-value; 0.02) and OS (3-y OS: 72.8% vs. 100%, HR; Inf (0.01-Inf), p-value=0.003). Multivariate analysis identified the presence of iENE (HR for EFS: 2.80, 95%CI: 0.97-8.05, HR for OS: 2.93, 95%CI: 1.01-8.44) and unresponsiveness to IC (HR for EFS: 2.47, 95%CI: 1.31-4.68, HR for OS: 2.87, 95%CI: 1.13-7.26) as mutually independent unfavorable prognostic factors for both EFS and OS. Furthermore, classification based on the two factors could identify the population with a worse prognosis (Table). Conclusions: In the sequential therapy of IC followed by CRT, the current study revealed for the first time that subjects with an iENE at baseline, together with an unsatisfactory response to IC would require special attention, such as more intensified post-treatment follow-up as well as additional therapeutic interventions to improve their prognosis. [Table: see text]
  • 翁長 龍太郎, 富岡 利文, 西谷 友樹雄, 岡野 渉, 篠﨑 剛, 松浦 一登, 林 隆一
    第33回日本頭頸部外科学会総会 2024年2月  

担当経験のある科目(授業)

 2